Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.
D000328:Adult; D018952:Antigens, CD34 / Q000378:metabolism; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D000077209:Decitabine; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D066298:In Vitro Techniques; D008745:Methylation; D010641:Phenotype; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D018800:Thy-1 Antigens / Q000378:metabolism
D018952:Antigens, CD34; D000964:Antimetabolites, Antineoplastic; D006877:Hydroxamic Acids; D011500:Protein Synthesis Inhibitors; D018800:Thy-1 Antigens; C012589:trichostatin A; D000077209:Decitabine; D001374:Azacitidine